Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 2416 AL 2430

Leukotrienes vs. Montelukast-Activity, Metabolism, and Toxicity Hints for Repurposing

Marques CF, Marques MM, Justino GC.

Pharmaceuticals (Basel). 2022 Aug 23;15(9):1039. doi: 10.3390/ph15091039.

Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases

Ashraf H, Solla P, Sechi LA.

Pharmaceuticals (Basel). 2022 Aug 29;15(9):1077. doi: 10.3390/ph15091077.

Binding of Natural Inhibitors to Respiratory Complex I

Schiller J, Zickermann V.

Pharmaceuticals (Basel). 2022 Aug 31;15(9):1088. doi: 10.3390/ph15091088.

Brain-Targeted Drug Delivery

Sousa F.

Pharmaceutics. 2022 Aug 31;14(9):1835. doi: 10.3390/pharmaceutics14091835.

A Review of Non-Invasive Drug Delivery through Respiratory Routes

Zhang YB, Xu D, Bai L, Zhou YM, Zhang H, Cui YL.

Pharmaceutics. 2022 Sep 19;14(9):1974. doi: 10.3390/pharmaceutics14091974.

MELAS syndrome with rare manifestations misdiagnosed as vasculitis in the absence of lactic acidosis: A case report

Alsultan M, Alshaar D, Alkhouli B, Hassan Q.

Ann Med Surg (Lond). 2022 Aug 27;81:104483. doi: 10.1016/j.amsu.2022.104483. eCollection 2022 Sep.

A review on the importance of miRNA-135 in human diseases

Kadkhoda S, Eslami S, Mahmud Hussen B, Ghafouri-Fard S.

Front Genet. 2022 Sep 6;13:973585. doi: 10.3389/fgene.2022.973585. eCollection 2022.

Mild cognitive impairment in patients with Parkinson's disease: An updated mini-review and future outlook

Yu RL, Wu RM.

Front Aging Neurosci. 2022 Sep 6;14:943438. doi: 10.3389/fnagi.2022.943438. eCollection 2022.

Multitargeting nature of muscarinic orthosteric agonists and antagonists

Myslivecek J.

Front Physiol. 2022 Sep 6;13:974160. doi: 10.3389/fphys.2022.974160. eCollection 2022.

Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role

Tyagi R, Vaidya B, Sharma SS.

Pharmacol Rep. 2022 Oct;74(5):790-817. doi: 10.1007/s43440-022-00417-5. Epub 2022 Sep 23.

SARS-CoV-2 mediated neurological disorders in COVID-19: Measuring the pathophysiology and immune response

Hsu PC, Shahed-Al-Mahmud M.

Life Sci. 2022 Nov 1;308:120981. doi: 10.1016/j.lfs.2022.120981. Epub 2022 Sep 21.

α-Syn overexpression, NRF2 suppression, and enhanced ferroptosis create a vicious cycle of neuronal loss in Parkinson's disease

A A, W C, N N, L M, M D, Zhang DD.

Free Radic Biol Med. 2022 Nov 1;192:130-140. doi: 10.1016/j.freeradbiomed.2022.09.015. Epub 2022 Sep 21.

Glycolysis: The Next Big Breakthrough in Parkinson's Disease

Naeem U, Arshad AR, Jawed A, Eqbal F, Imran L, Khan Z, Ijaz F.

Neurotox Res. 2022 Dec;40(6):1707-1717. doi: 10.1007/s12640-022-00579-3. Epub 2022 Sep 24.

Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson's disease

Pang M, Peng R, Wang Y, Zhu Y, Wang P, Moussian B, Su Y, Liu X, Ming D.

Biomed Pharmacother. 2022 Nov;155:113718. doi: 10.1016/j.biopha.2022.113718. Epub 2022 Sep 21.

Prevalence and associated factors of dry skin among older inpatients in hospitals and nursing homes: A multicenter cross-sectional study

Jiang Q, Wang Y, Liu Y, Zhu D, Xie Y, Zhao J, Weng Y, Tang Y, Feng H, Li Y, Wang J, Cai Y, Kang Z, Ou Y, Chen D.

Int J Nurs Stud. 2022 Nov;135:104358. doi: 10.1016/j.ijnurstu.2022.104358. Epub 2022 Aug 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias